Sustainable Solutions for Today and Into the Future
Chorionic Gonadotropin, ≥95% | Chorionic Gonadotropin, ≥80% | Chorionic Gonadotropin, ß-Subunit | Follicle Stimulating Hormone | Luteinizing Hormone-CHO | Luteinizing Hormone-HEK293| Prolactin | Thyroid Stimulating Hormone
Human Chorionic Gonadotropin
Recent disruptions in the supply of starting material for Human Chorionic Gonadotropin (hCG) production have impacted the manufacture of native hCG across the globe. Scripps Laboratories, however, foresaw the coming starting material shortage and developed high quality recombinant forms of hCG and ß-hCG, both of which are in stock and available now.
hCG is produced by the trophoblastic cells of the placenta during pregnancy. hCG levels rise shortly after a fertilized egg is implanted in the uterine wall and remain elevated above normal levels throughout the pregnancy, usually peaking during weeks 8-10. Qualitative tests for hCG are used to detect pregnancy, while quantitative tests may be used to diagnose abnormal pregnancies, identify possible miscarriages, screen for Down syndrome, and aid in determining the exact age of the fetus. Quantitative tests for the ß-subunit of hCG (ß-hCG) are used to help diagnose testicular cancer, ovarian and testicular germ cell tumors, and gestational trophoblastic disease.
Our recombinant hCG & ß-hCG are suitable for use in both qualitative and quantitative hCG immunoassays, as well as in research applications. Both products have been widely tested and are remarkably similar to their native counterparts.
Several recombinant hCG products are available:
Follicle Stimulating Hormone
Recombinant Follicle Stimulating Hormone (hFSH) was the first glycosylated, multi-subunit, recombinant hormone to be release by Scripps Laboratories. It passed customer evaluations immediately and has been approved for use in multiple clinical diagnostic assay systems.
Testing for hFSH is on the rise globally, as it is a valuable marker of fertility and reproductive dysfunction in women and men. With the dire shortage and rising cost of native human starting materials, recombinant proteins are proving to be the only sensible solution for sustained long-term supply. Recombinant hFSH from Scripps has been tested and approved, and it is available for your research, assay development, and large-scale manufacturing needs today.
Scripps Laboratories has supplied the world with high quality native Human Luteinizing Hormone (hLH) for decades, but worldwide starting material shortages have impacted our ability to continue producing the large amounts of hLH needed to support the diagnostic industry. In response to this, we developed a glycosylated, recombinant form of hLH that reacts similarly to native hLH in a variety of antibody-based assay systems.
hLH is produced by the anterior pituitary gland and stimulates the ovaries to produce estradiol, which induces the maturation and subsequent release of an egg. As such, serial hLH testing is effective in helping identify the optimal days of fertility. In addition, sustained hLH elevations may indicate the onset of menopause. Fertility rates are on the decline globally and the demand for fertility tests, such as those for hFSH and hLH, are expected to nearly doubly by 2028.
With native hLH in short supply, Recombinant hLH from Scripps is an excellent, sustainable option to support your research and assay development efforts. Material is in stock and available now.
Recombinant Human Prolactin (hPRL) was the first recombinant product released by Scripps Laboratories, in 2001. It has been used in research and clinical diagnostic immunoassay development for more than 20 years and is an exceptionally stable and reliable product.
hPRL is produced by the anterior pituitary gland and is responsible for lactation, certain breast tissue development and lactation during pregnancy. In addition, it is involved in several other bodily processes and may play a role in tumorigenesis and in assessing cancer risk (See ScrippsNews V16N1.) Testing for hPRL is used to detect pituitary gland tumors and also to help assess the cause of infertility and menstrual dysfunction.
The global supply of native hPRL is on the decline, due to starting material shortages, so Recombinant hPRL from Scripps Laboratories is an effective, reliable, and economical alternative. Recombinant hPRL is in stock and available now.
Thyroid Stimulating Hormone
The deficiency of starting material has also impacted native Human Thyroid Stimulating Hormone (hTSH), placing it in short supply and significantly increasing its cost to manufacture. Fortunately, Scripps Laboratories developed a recombinant, glycosylated form of hTSH that is immunoreactive and comparable to native hTSH.
hTSH is produced by the anterior pituitary gland and regulates the function of the thyroid gland. It stimulates the production and release of triiodothyronine (T3) and thyroxine (T4), which help regulate an individual’s weight, temperature, hair and nail growth, brain function, bone health, and several other bodily processes. Thyroid disease is a very common affliction and the worldwide demand for hTSH testing is high. This strains the availability of native hTSH and underscores the importance of recombinant proteins today and into the future.
Recombinant hTSH from Scripps Laboratories has been well-received and is demonstrated to perform similarly to native hTSH, making it an ideal replacement for native hTSH. Recombinant hTSH is in stock and available for testing now.